pembrolizumab   Click here for help

GtoPdb Ligand ID: 7499

Synonyms: Keytruda® | lambrolizumab | MK-3475
Approved drug Immunopharmacology Ligand
pembrolizumab is an approved drug (FDA (2014), EMA (2015))
Compound class: Antibody
Comment: Pembrolizumab is the first-in-class, anti-PD-1 antibody to be approved by the US FDA.
Full peptide sequence and disulphide bond information is available from the IMGT/mAb-DB entry for this antibody.

Pembrolizumab is the first immuno-oncology therapeutic to be approved for use in cancers of any tissue type, so long as they express a specific genetic biomarker (i.e. high microsatellite instability (MSI-H) or mismatch repair deficient (dMMR) tumours). This is an important breakthrough, since up until this point FDA approvals, including earlier approvals for pembrolizumab, had always been restricted to certain tissue-specific cancers.
Click here for help
Immunopharmacology Comments
Included in GtoImmuPdb as it is an immune checkpoint inhibitor, not because it is a therapeutic for inflammatory conditions. Pembrolizumab is being evaluated in clinical trial in combination with the first-in-class anti-CD16A (FcγRIIIA)/CD30 bispecific tandem diabody AFM13 (a NK cell engaging strategy aimed at maximising ADCC - see NCT02665650, Phase 1) for relapsed/refractory classical Hodgkin lymphoma.